{
  "docId": "019de075-d6ea-7495-b63c-e64074d45b72",
  "docSlug": "3f99bbe59467be363a98d21e99cb078a",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 58,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "Includes comparative bar charts and flow cytometry data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/9",
  "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72",
  "deckJsonHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72.json",
  "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.78,
        "y": 0.54
      },
      "kind": "chart",
      "text": "Low Tonic Signaling TNFa concentration",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a63b87e-39b9-4dac-84e8-8941b6b2c133",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.78,
        "y": 0.34
      },
      "kind": "chart",
      "text": "High Transduction Efficiency comparison",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5449cfc6-f950-4546-90a9-53785f4eebb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.78,
        "y": 0.74
      },
      "kind": "chart",
      "text": "Anti-Exhaustion Capability flow cytometry",
      "attrs": null,
      "subkind": "histogram",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff420e90-672d-4f16-9300-890c8547bfb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.14,
        "y": 0.0033
      },
      "kind": "image",
      "text": "Diagram of BCMA expressing cancer cell and NXC-201 CAR-T cell interaction",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "086f0a9b-38ff-4157-8cd3-37aa61c2f809",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.02,
        "y": 0.74
      },
      "kind": "list",
      "text": "NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) produced by our N-GENIUS platform targeting B-cell maturation antigen (BCMA). High Overall Response Rates in AL Amyloidosis and Multiple Myeloma. First Outpatient CAR-T: Short CRS duration (median 2 days) starting on day 0. No Neurotoxicity, only 1 grade 3 CRS across 42 Multiple Myeloma patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eed4e1e0-177b-437c-a976-a874533b42c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f3cbd8b-5a9e-45a5-90ab-5c540a1e7185",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.17,
        "y": 0.0018
      },
      "kind": "title",
      "text": "NXC-201: FIRST BCMA CAR-T GENERATED BY THE N-GENIUS PLATFORM",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b89ff9db-7991-40df-82a9-9eee96fb0f93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 MoA: Next Generation CAR-T For Multiple Myeloma and AL Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a261de3e-4f97-4482-a239-82ca1c3d232f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "9a5cf780-a5dc-4d85-9da7-f76ccdc54326",
      "evidence": "NXC-201: FIRST BCMA CAR-T GENERATED BY THE N-GENIUS PLATFORM",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 27,
      "from": 4,
      "beatId": "e890a8f4-ce5b-494a-9258-fdd0f87cc84b",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Interest",
      "beatSlug": "aida-interest",
      "evidence": "The deck presents the problem, solution, competitive analysis, and traction",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 9,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "8d02a94e-79b8-4ba4-920c-87f81d998140",
      "evidence": "The deck presents NXC-201's MoA and clinical highlights",
      "position": 0,
      "objective": "Understanding NXC-201's mechanism of action",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}